Summary of COVID-19 YKYY017 studies

1. Wang et al., The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial

239 patient YKYY017 early treatment RCT: 31% improved recovery (p=0.003) and 13% improved viral load (p=0.08).
RCT 239 mostly mild COVID-19 outpatients showing the primary endpoint of viral load reduction at day 4 was not met with inhaled peptide YKYY017. The 20mg group showed significantly faster time to recovery. The study population was low-risk, with only one patient progressing to severe disease.
Aug 2025, Nature Communication, https://www.nature.com/articles/s41467-025-62214-x, https://c19p.org/wang53